Botox Cosmetic was recently approved for the treatment of platysma bands, making it the first neurotoxin to be approved for four indications. This approval allows for marketing directly to consumers, increasing awareness of this nonsurgical solution. Phase 3 clinical trials showed significant improvement in the appearance of platysma bands with Botox Cosmetic compared to a placebo. This approval provides a safe and effective treatment option for patients, with standardized training for providers. While the approval doesn’t add new treatment capabilities for experienced practitioners, it enhances patient awareness and education on non-surgical options for platysma bands.
Source link
Botox Cosmetic’s FDA approval may lead to higher visibility, more patient inquiries
